Fixed dosing of HER antibodies

What is this patent about?

’234 is related to the field of oncology and the therapeutic administration of monoclonal antibodies. Specifically, it addresses the pharmacological management of HER family receptors, such as HER2, which are frequently overexpressed in breast, ovarian, and lung cancers. Traditionally, these high-molecular-weight biologics have been administered using weight-based or body-surface-area-based calculations to account for physiological differences between patients.

The underlying idea behind ’234 is that the pharmacokinetic variability of humanized IgG1 antibodies, specifically pertuzumab, is not significantly reduced by individualized weight-based dosing. Through population modeling, the inventors discovered that while body weight and surface area are measurable covariates, they explain only a negligible fraction of the differences in drug clearance between patients. Consequently, the complexity of individualized dosing provides no clinical advantage over a standardized, absolute amount of the drug.

The claims of ’234 focus on an article of manufacture designed for standardized delivery, specifically a single-dose vial containing a fixed amount of pertuzumab. The independent claims protect specific dosage strengths of either 420 mg or 840 mg, corresponding to maintenance and loading doses respectively. This protection extends to the specific molecular structure of the antibody, defined by the variable light and heavy amino acid sequences that characterize the HER2 dimerization inhibitor.

In practice, the invention is implemented through a 20 cc vial pre-filled with 420 mg of the antibody, facilitating a streamlined clinical workflow. By utilizing a linear 2-compartment model, the inventors demonstrated that steady-state trough concentrations remain within therapeutic targets across diverse patient populations when using these fixed amounts. This approach shifts the burden of dose calculation away from the pharmacy and bedside, relying instead on the inherent stability and predictable clearance rates of the humanized IgG1 framework.

This invention differs from prior approaches by abandoning the industry-standard mg/kg dosing paradigm in favor of flat-fixed dosing. Unlike previous methods that risked calculation errors and medication waste, this standardized format improves manufacturing efficiency and ensures that patients with extreme body weights still achieve the necessary target drug concentrations. By proving that individualized scaling does not actually improve the predictability of drug exposure, the patent provides a more robust and efficient delivery mechanism for HER2-targeted therapies.